J
Jonas Abrahamsson
Researcher at Boston Children's Hospital
Publications - 21
Citations - 805
Jonas Abrahamsson is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Transplantation & Whole genome sequencing. The author has an hindex of 13, co-authored 21 publications receiving 692 citations. Previous affiliations of Jonas Abrahamsson include Sahlgrenska University Hospital & University of Gothenburg.
Papers
More filters
Journal ArticleDOI
Emergence of New ALK Mutations at Relapse of Neuroblastoma
Gudrun Schleiermacher,Niloufar Javanmardi,Virginie Bernard,Quentin Leroy,Julie Cappo,Thomas Rio Frio,Gaëlle Pierron,Eve Lapouble,Valérie Combaret,Franki Speleman,Bram De Wilde,Anna Djos,Ingrid Øra,Fredrik Hedborg,Catarina Träger,Britt-Marie Holmqvist,Jonas Abrahamsson,Michel Peuchmaur,Jean Michon,Isabelle Janoueix-Lerosey,Per Kogner,Olivier Delattre,Tommy Martinsson +22 more
TL;DR: In neuroblastoma, subclonal ALK mutations can be present at diagnosis with subsequent clonal expansion at relapse, highlighting the potential of deep sequencing for detection of sub clonal mutations with a sensitivity 100-fold that of Sanger sequencing and the importance of serial samplings for therapeutic decisions.
Journal ArticleDOI
Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004
Henrik Hasle,Jonas Abrahamsson,Erik Forestier,Shau-Yin Ha,Jesper Heldrup,Kirsi Jahnukainen,Olafur Gisli Jonsson,Birgitte Lausen,Josefine Palle,Bernward Zeller +9 more
TL;DR: GO therapy postconsolidation as given in this trial was well tolerated, showed a nonsignificant delay in time to relapse, but did not change the rate of relapse or survival.
Journal ArticleDOI
Improved outcome after relapse in children with acute myeloid leukaemia
Jonas Abrahamsson,Niels Clausen,Göran Gustafsson,Liisa Hovi,Gudmundur Jonmundsson,Bernward Zeller,Erik Forestier,Jesper Heldrup,Henrik Hasle +8 more
TL;DR: A significant proportion of children with relapsed AML can be cured, even those with early relapse, and children who receive re‐induction therapy, enter remission and proceed to SCT can achieve a cure rate of 60%.
Journal ArticleDOI
Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia
Anna Staffas,Meena Kanduri,Randi Hovland,Richard Rosenquist,Hans Beier Ommen,Jonas Abrahamsson,Erik Forestier,Kirsi Jahnukainen,Olafur G. Jonsson,Bernward Zeller,Josefine Palle,Gudmar Lönnerholm,Henrik Hasle,Lars Palmqvist,Hans Ehrencrona,Hans Ehrencrona +15 more
TL;DR: Analysis of the mutational status of FLT3 and NPM1 at diagnosis is important for prognostic stratification of patients with pediatric AML and that determination of the BAALC gene expression level can add valuable information.
Journal ArticleDOI
Pathways through relapses and deaths of children with acute lymphoblastic leukemia: role of allogeneic stem-cell transplantation in Nordic data.
Ulla M. Saarinen-Pihkala,Carsten Heilmann,Jacek Winiarski,Anders Glomstein,Jonas Abrahamsson,Johan Arvidson,Albert N. Békássy,Erik Forestier,Gudmundur Jonmundsson,Henrik Schroeder,Kim Vettenranta,Finn Wesenberg,Göran Gustafsson +12 more
TL;DR: After relapse, more patients were lost to mortality as a result of toxicity during conventional chemotherapy compared with TRM, and the question of whether transplantation is recommended after ALL relapse should be carefully addressed, and more efficient relapse protocols should be launched.